MGAT5 drives melanoma aggressiveness via TIMP1 glycosylation–dependent CD63–β1-integrin signaling
Translational Research · 2026-11 · 297 · 242-254
DOI: 10.1016/j.trsl.2026.09.012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Translational Research, 2026-11. Verfasst von Beatriz Laís Justo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil. Hauptthemen laut MEDLINE: Tissue Inhibitor of Metalloproteinase-1, Signal Transduction, Melanoma, Integrin beta1. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação de Amparo à Pesquisa do Estado de São Paulo, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.
Abstract (Originalsprache)
MGAT5-mediated N-glycosylation plays a central role in tumor progression and metastasis by affecting proteins involved in tumor cell behavior. One relevant target is Tissue inhibitor of metalloproteases 1 (TIMP1), which, beyond its classical role as a metalloproteinase inhibitor, promotes oncogenic signaling through interactions with CD63 and β1-integrins. Emerging evidence suggests that aberrant TIMP1 N-glycosylation may regulate these diverse functions. Here, we investigated the role of MGAT5 in melanoma cell behavior and how MGAT5-mediated aberrant N-glycosylation influences TIMP1 function, including its activity as a signaling molecule and as an inhibitor of metalloproteinases. We performed Mgat5 knockout using CRISPR/Cas9 in metastatic melanoma cells to understand the role of MGAT5 in cell proliferation, migration, invasion, and tumor growth. Through site-directed mutagenesis, we generated melanoma cells expressing aglycosylated TIMP1 and evaluated the effect of N-glycosylation on TIMP1 function, including its role as a signaling molecule, by co-immunoprecipitation and anoikis resistance assays, and as an inhibitor of metalloproteinases, by zymography. We demonstrated that Mgat5 knockout reduced metastatic melanoma cell proliferation, migration, invasion, and tumor growth, TIMP1 is a target of MGAT5 in metastatic melanoma cells, and aberrant glycosylation of TIMP1 favors its interaction with CD63/β1-integrins and cell survival while decreasing its ability to inhibit metalloproteases (MMPs). Therefore, MGAT5 plays a pro-tumor role in metastatic melanoma cells and the aberrant glycoform of TIMP1 directs its function as a signaling molecule, orchestrating the pleiotropic functions of TIMP1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil.
- Department of Biophysics, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil.
- Department of Pharmacology, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil. Electronic address: mgjasiulionis@unifesp.br.
Förderung
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
Zitieren
APA
Justo, B. L., Lengert, A. V. H., Han, S. W., & Jasiulionis, M. G. (2026). MGAT5 drives melanoma aggressiveness via TIMP1 glycosylation–dependent CD63–β1-integrin signaling. Translational Research, 297, 242-254. https://doi.org/10.1016/j.trsl.2026.09.012
Vancouver
Justo BL, Lengert AVH, Han SW, Jasiulionis MG. MGAT5 drives melanoma aggressiveness via TIMP1 glycosylation–dependent CD63–β1-integrin signaling. Translational Research. 2026;297:242-254. doi:10.1016/j.trsl.2026.09.012
BibTeX
@article{Justo2026,
author = {Justo, Beatriz Laís and Lengert, André van Helvoort and Han, Sang Won and Jasiulionis, Miriam Galvonas},
title = {MGAT5 drives melanoma aggressiveness via TIMP1 glycosylation–dependent CD63–β1-integrin signaling},
journal = {Translational Research},
year = {2026},
volume = {297},
pages = {242--254},
doi = {10.1016/j.trsl.2026.09.012}
}
EUVIMED